An Open-Label Study of XOMA 358, with Optional Dose Escalation, in Patients with Congenital Hyperinsulinism
Latest Information Update: 04 Jun 2020
At a glance
- Drugs Ersodetug (Primary)
- Indications Hyperinsulinaemia; Hypoglycaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors XOMA
- 01 Jun 2020 Results published in Rezolute Media Release
- 01 Jun 2020 According to a Rezolute media release, results from this trial were present at the Pediatric Endocrine Society (PES) 2020 Annual Meeting, held virtually
- 04 Apr 2017 Results assessing activity of Xoma-358, following short-term administration to congenital hyperinsulinism patients (X358602 and X358605 Congenital Hyperinsulinism studies), presented at The 99th Annual Meeting of the Endocrine Society.